Nasdaq · CIK 0001850119
IPSC Century Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 27 d ago. Close $1.47 on Oct 9, 2026, +216% from the 52-week low and -50% from the high.
Last 90 days
Net insider value
-$9,808
more sold than bought
Buys
0
$0 by 0 insiders
Sells
4
$9,808 by 2 insiders
Insiders on file
14
with a Form 4 at this company
Price and insider trades, last year
IPSCOct 9, 2026 · close 1.47
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Century Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 23Weak | Douglas Carr SVP Finance & Operations sell | $3,200 1,658 shares | -0% | - | |
| 23Weak | Gregory Russotti See Remarks sell | $4,993 2,587 shares | -1% | - | |
| 23Weak | Douglas Carr SVP Finance & Operations sell | $521 254 shares | -0% | - | |
| 23Weak | Gregory Russotti See Remarks sell | $1,095 534 shares | -0% | - | |
| 30Weak | Douglas Carr SVP Finance & Operations sell | $3,050 4,904 shares | -1% | +61% from low-64% from high | |
| 30Weak | Gregory Russotti See Remarks sell | $327 526 shares | -0% | +61% from low-64% from high | |
| 40Moderate | Brent Pfeiffenberger President and CEO sell | $295 475 shares | -0% | +61% from low-64% from high | |
| 35Weak | Adrienne Farid Chief Operations Officer sell | $343 552 shares | -0% | +61% from low-64% from high | |
| 40Moderate | Brent Pfeiffenberger President and CEO sell | $16k 29,552 shares | -2% | +44% from low-67% from high | |
| 30Weak | Douglas Carr SVP Finance & Operations sell | $162 295 shares | -0% | +44% from low-67% from high | |
| 35Weak | Adrienne Farid Chief Operations Officer sell | $563 1,024 shares | -0% | +44% from low-67% from high | |
| 30Weak | Douglas Carr SVP Finance & Operations sell | $763 1,240 shares | -0% | - | |
| 35Weak | Adrienne Farid Chief Operations Officer sell | $1,451 2,359 shares | -2% | - | |
| 30Weak | Gregory Russotti See Remarks sell | $1,451 2,360 shares | -1% | - | |
| 40Moderate | Brent Pfeiffenberger President and CEO sell | $1,375 2,235 shares | -0% | - | |
| 30Weak | Brent Pfeiffenberger President and CEO sell | $27k 34,712 shares | -3% | - | |
| 23Weak | Douglas Carr SVP Finance & Operations sell | $274 351 shares | -0% | - | |
| 28Weak | Adrienne Farid Chief Operations Officer sell | $822 1,054 shares | -1% | - | |
| 23Weak | Douglas Carr SVP Finance & Operations sell | $347 283 shares | -0% | - | |
| 28Weak | Adrienne Farid Chief Operations Officer sell | $1,267 1,033 shares | -1% | - |
Transactions
The last 46 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | Gregory Russotti See Remarks | SOpen-market sale Common Stock | -2,587 | $1.93 | $4,993 | 509,198 | 27 d ago |
| Sep 11, 2026 | Brent Pfeiffenberger President and CEO | FTax withholding Common Stock | -13,850 | $1.94 | $27k | 3,633,839 | 27 d ago |
| Sep 14, 2026 | Douglas Carr SVP Finance & Operations | SOpen-market sale Common Stock | -1,658 | $1.93 | $3,200 | 502,907 | 27 d ago |
| Sep 9, 2026 | Joseph Truitt director | AGrant or award Stock Option (right to buy)derivative | +148,000 | $0.00 | $0 | 148,000 | 32 d ago |
| Sep 8, 2026 | Douglas Carr SVP Finance & Operations | SOpen-market sale Common Stock | -254 | $2.05 | $521 | 504,565 | 33 d ago |
| Sep 8, 2026 | Gregory Russotti See Remarks | SOpen-market sale Common Stock | -534 | $2.05 | $1,095 | 511,785 | 33 d ago |
| Sep 4, 2026 | Brent Pfeiffenberger President and CEO | FTax withholding Common Stock | -463 | $2.11 | $977 | 3,633,839 | 33 d ago |
| Jun 12, 2025 | Cynthia M Butitta director | AGrant or award Stock Option (right to buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Jun 16, 2025 |
| Jun 12, 2025 | Kimberly Blackwell director | AGrant or award Stock Option (right to buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Jun 16, 2025 |
| Jun 12, 2025 | Rizzuto Carlo director | AGrant or award Stock Option (right to buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Jun 16, 2025 |
| Jun 12, 2025 | Timothy P Walbert director | AGrant or award Stock Option (right to buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Jun 16, 2025 |
| Jun 12, 2025 | Daphne Quimi director | AGrant or award Stock Option (right to buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Jun 16, 2025 |
| Jun 12, 2025 | Alessandro Riva director | AGrant or award Stock Option (right to buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Jun 16, 2025 |
| Jun 12, 2025 | Joseph Jimenez director | AGrant or award Stock Option (right to buy)derivative | +44,000 | $0.00 | $0 | 44,000 | Jun 16, 2025 |
| Jun 9, 2025 | Douglas Carr SVP Finance & Operations | SOpen-market sale Common Stock | -4,904 | $0.62 | $3,050 | 405,982 | Jun 11, 2025 |
| Jun 9, 2025 | Adrienne Farid Chief Operations Officer | SOpen-market sale Common Stock | -552 | $0.62 | $343 | 250,141 | Jun 11, 2025 |
| Jun 9, 2025 | Brent Pfeiffenberger President and CEO | SOpen-market sale Common Stock | -475 | $0.62 | $295 | 1,681,783 | Jun 11, 2025 |
| Jun 9, 2025 | Gregory Russotti See Remarks | SOpen-market sale Common Stock | -526 | $0.62 | $327 | 392,047 | Jun 11, 2025 |
| May 16, 2025 | Brent Pfeiffenberger President and CEO | SOpen-market sale Common Stock | -29,552 | $0.55 | $16k | 1,682,258 | May 20, 2025 |
| May 5, 2025 | Douglas Carr SVP Finance & Operations | SOpen-market sale Common Stock | -295 | $0.55 | $162 | 410,886 | May 7, 2025 |
| May 5, 2025 | Adrienne Farid Chief Operations Officer | SOpen-market sale Common Stock | -1,024 | $0.55 | $563 | 250,693 | May 7, 2025 |
| Mar 10, 2025 | Brent Pfeiffenberger President and CEO | SOpen-market sale Common Stock | -2,235 | $0.62 | $1,375 | 1,190,310 | Mar 12, 2025 |
| Mar 10, 2025 | Gregory Russotti See Remarks | SOpen-market sale Common Stock | -2,360 | $0.62 | $1,451 | 272,573 | Mar 12, 2025 |
| Mar 10, 2025 | Adrienne Farid Chief Operations Officer | SOpen-market sale Common Stock | -2,359 | $0.62 | $1,451 | 131,717 | Mar 12, 2025 |
| Mar 10, 2025 | Douglas Carr SVP Finance & Operations | SOpen-market sale Common Stock | -1,240 | $0.62 | $763 | 315,556 | Mar 12, 2025 |
| Mar 11, 2025 | Morgan Conn Chief Finanical Officer | AGrant or award Common Stock | +19,500 | $0.00 | $0 | 79,648 | Mar 12, 2025 |
| Mar 11, 2025 | Chad Cowan Chief Scientific Officer | AGrant or award Common Stock | +19,500 | $0.00 | $0 | 230,306 | Mar 12, 2025 |
| Mar 11, 2025 | Adrienne Farid Chief Operations Officer | AGrant or award Common Stock | +120,000 | $0.00 | $0 | 251,717 | Mar 12, 2025 |
| Mar 11, 2025 | Morgan Conn Chief Finanical Officer | AGrant or award Stock Option (right to buy)derivative | +19,500 | $0.00 | $0 | 19,500 | Mar 12, 2025 |
| Mar 11, 2025 | Brent Pfeiffenberger President and CEO | AGrant or award Common Stock | +521,500 | $0.00 | $0 | 1,711,810 | Mar 12, 2025 |
| Mar 11, 2025 | Gregory Russotti See Remarks | AGrant or award Common Stock | +120,000 | $0.00 | $0 | 392,573 | Mar 12, 2025 |
| Mar 11, 2025 | Douglas Carr SVP Finance & Operations | AGrant or award Common Stock | +95,625 | $0.00 | $0 | 411,181 | Mar 12, 2025 |
| Mar 11, 2025 | Chad Cowan Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +19,500 | $0.00 | $0 | 19,500 | Mar 12, 2025 |
| Mar 11, 2025 | Adrienne Farid Chief Operations Officer | AGrant or award Stock Option (right to buy)derivative | +120,000 | $0.00 | $0 | 120,000 | Mar 12, 2025 |
| Mar 11, 2025 | Douglas Carr SVP Finance & Operations | AGrant or award Stock Option (right to buy)derivative | +95,625 | $0.00 | $0 | 95,625 | Mar 12, 2025 |
| Mar 11, 2025 | Brent Pfeiffenberger President and CEO | AGrant or award Stock Option (right to buy)derivative | +521,500 | $0.00 | $0 | 521,500 | Mar 12, 2025 |
| Mar 11, 2025 | Gregory Russotti See Remarks | AGrant or award Stock Option (right to buy)derivative | +120,000 | $0.00 | $0 | 120,000 | Mar 12, 2025 |
| Feb 18, 2025 | Brent Pfeiffenberger President and CEO | SOpen-market sale Common Stock | -34,712 | $0.78 | $27k | 1,192,545 | Feb 20, 2025 |
| Feb 3, 2025 | Douglas Carr SVP Finance & Operations | SOpen-market sale Common Stock | -351 | $0.78 | $274 | 316,796 | Feb 5, 2025 |
| Feb 3, 2025 | Adrienne Farid Chief Operations Officer | SOpen-market sale Common Stock | -1,054 | $0.78 | $822 | 134,076 | Feb 5, 2025 |
| Dec 4, 2024 | Brent Pfeiffenberger President and CEO | FTax withholding Common Stock | -243,447 | $1.44 | $351k | 1,227,257 | Dec 6, 2024 |
| Nov 4, 2024 | Adrienne Farid Chief Operations Officer | SOpen-market sale Common Stock | -1,033 | $1.23 | $1,267 | 135,130 | Nov 5, 2024 |
| Nov 1, 2024 | Douglas Carr SVP Finance & Operations | FTax withholding Common Stock | -16,611 | $1.26 | $21k | 317,430 | Nov 5, 2024 |
| Nov 4, 2024 | Douglas Carr SVP Finance & Operations | SOpen-market sale Common Stock | -283 | $1.23 | $347 | 317,147 | Nov 5, 2024 |
| Oct 14, 2024 | Morgan Conn Chief Finanical Officer | AGrant or award Common Stock | +60,148 | $0.00 | $0 | 60,148 | Oct 16, 2024 |
| Oct 14, 2024 | Morgan Conn Chief Finanical Officer | AGrant or award Stock Option (right to buy)derivative | +360,890 | $0.00 | $0 | 360,890 | Oct 16, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Cynthia M Butittadirector
- Kimberly Blackwelldirector
- Rizzuto Carlodirector
- Douglas CarrSVP Finance & Operations
- Morgan ConnChief Finanical Officer
- Chad CowanChief Scientific Officer
- Adrienne FaridChief Operations Officer
- Joseph Jimenezdirector
- Brent PfeiffenbergerPresident and CEO
- Daphne Quimidirector
- Alessandro Rivadirector
- Gregory RussottiSee Remarks
- Joseph Truittdirector
- Timothy P Walbertdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.